Spirapril HCl

    WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H318753

CAS#: 94841-17-5 (HCl)

Description: Spirapril is an ACE inhibitor antihypertensive drug used to treat hypertension. It belongs to dicarboxy group of ACE inhibitors.

Chemical Structure

img
Spirapril HCl
CAS# 94841-17-5 (HCl)
Instruction

Theoretical Analysis

Hodoodo Cat#: H318753
Name: Spirapril HCl
CAS#: 94841-17-5 (HCl)
Chemical Formula: C22H31ClN2O5S2
Exact Mass: 466.16
Molecular Weight: 503.069
Elemental Analysis: C, 52.53; H, 6.21; Cl, 7.05; N, 5.57; O, 15.90; S, 12.75

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 83647-97-6 (free base)   94841-17-5 (HCl)   200872-06-6 (HCl hydrate)    

Synonym: BRN4277924; BRN-4277924; BRN 4277924; Spirapril; Spiraprilum; Espirapril; Spirapril HCl; Spirapril hydrochloride

IUPAC/Chemical Name: (S)-7-(((S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl)-L-alanyl)-1,4-dithia-7-azaspiro[4.4]nonane-8-carboxylic acid hydrochloride

InChi Key: CLDOLNORSLLQDI-OOAIBONUSA-N

InChi Code: InChI=1S/C22H30N2O5S2.ClH/c1-3-29-21(28)17(10-9-16-7-5-4-6-8-16)23-15(2)19(25)24-14-22(30-11-12-31-22)13-18(24)20(26)27;/h4-8,15,17-18,23H,3,9-14H2,1-2H3,(H,26,27);1H/t15-,17-,18-;/m0./s1

SMILES Code: O=C([C@H](C1)N(C([C@H](C)N[C@@H](CCC2=CC=CC=C2)C(OCC)=O)=O)CC31SCCS3)O.[H]Cl

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info: Related CAS# CAS#83647-97-6 (Spirapril free base) CAS#94841-17-5 ( Spirapril HCl) CAS#200872-06-6 (Spirapril hydrochloride monohydrate)

Biological target:
In vitro activity:
In vivo activity:

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
Soluble in DMSO, not in water 0.0 100.00

Preparing Stock Solutions

The following data is based on the product molecular weight 503.07 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Hermida RC, Ayala DE, Fernández JR, Mojón A, Smolensky MH, Fabbian F, Portaluppi F. Administration-time differences in effects of hypertension medications on ambulatory blood pressure regulation. Chronobiol Int. 2013 Mar;30(1-2):280-314. doi: 10.3109/07420528.2012.709448. Epub 2012 Oct 19. Review. PubMed PMID: 23077971.

2: Hermida RC, Ayala DE, Fernández JR, Portaluppi F, Fabbian F, Smolensky MH. Circadian rhythms in blood pressure regulation and optimization of hypertension treatment with ACE inhibitor and ARB medications. Am J Hypertens. 2011 Apr;24(4):383-91. doi: 10.1038/ajh.2010.217. Epub 2010 Oct 7. Review. PubMed PMID: 20930708.

3: Song JC, White CM. Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update. Clin Pharmacokinet. 2002;41(3):207-24. Review. PubMed PMID: 11929321.

4: Byrn SR, Xu W, Newman AW. Chemical reactivity in solid-state pharmaceuticals: formulation implications. Adv Drug Deliv Rev. 2001 May 16;48(1):115-36. Review. PubMed PMID: 11325479.

5: Elliot HL. [The ACE inhibitor spirapril in chronic renal failure, hypertension and diabetic nephropathy]. Ter Arkh. 2000;72(10):78-82. Review. Russian. PubMed PMID: 11220886.

6: Ding PY, Hu OY, Pool PE, Liao W. Does Chinese ethnicity affect the pharmacokinetics and pharmacodynamics of angiotensin-converting enzyme inhibitors? J Hum Hypertens. 2000 Mar;14(3):163-70. Review. PubMed PMID: 10694829.

7: Jardine AG, Elliott HL. ACE inhibition in chronic renal failure and in the treatment of diabetic nephropathy: focus on spirapril. J Cardiovasc Pharmacol. 1999 Aug;34 Suppl 1:S31-4. Review. PubMed PMID: 10499562.

8: Hayduk K, Kraul H. Efficacy and safety of spirapril in mild-to-moderate hypertension. J Cardiovasc Pharmacol. 1999 Aug;34 Suppl 1:S19-23. Review. PubMed PMID: 10499560.

9: Fischler MP, Follath F. [Comparative evaluation of ACE inhibitors: which differences are relevant?]. Schweiz Med Wochenschr. 1999 Jul 27;129(29-30):1053-60. Review. German. PubMed PMID: 10464907.

10: Goyal RK. Hyperinsulinemia and insulin resistance in hypertension: differential effects of antihypertensive agents. Clin Exp Hypertens. 1999 Jan-Feb;21(1-2):167-79. Review. PubMed PMID: 10052652.

11: Noble S, Sorkin EM. Spirapril. A preliminary review of its pharmacology and therapeutic efficacy in the treatment of hypertension. Drugs. 1995 May;49(5):750-66. Review. PubMed PMID: 7601014.

12: Dahlöf B. Angiotensin-converting enzyme inhibitors and effects on left ventricular hypertrophy. Blood Press Suppl. 1994;2:35-40. Review. PubMed PMID: 8061844.

13: Elliott HL. Clinical use of angiotensin-converting enzyme inhibitors in patients with renal impairment. Blood Press Suppl. 1994;2:31-4. Review. PubMed PMID: 8061843.

14: Jerie P, Kremer HJ. Renpress, Sandopril (Spirapril/TI 211-950). Summary of chemical, pharmacological and clinical properties. Cor Vasa. 1992;34(1):82-7. Review. PubMed PMID: 1288944.

15: Salvetti A. Newer ACE inhibitors. A look at the future. Drugs. 1990 Dec;40(6):800-28. Review. PubMed PMID: 2078997.

16: McAreavey D, Robertson JI. Angiotensin converting enzyme inhibitors and moderate hypertension. Drugs. 1990 Sep;40(3):326-45. Review. PubMed PMID: 2226219.